Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A and C conjugate vaccine (Sinopharm)
- Development stage
- Unknown
- Lead developer
- Chengdu Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The group A and C meningococcal conjugate vaccine is a bivalent vaccine designed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A and C. Unlike pure polysaccharide vaccines, conjugate vaccines chemically link the bacterial capsular polysaccharides to a carrier protein (such as tetanus toxoid or CRM197). This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which induces a more robust immune response, provides longer-lasting immunity, and is effective in infants and young children under two years of age. Several Chinese biopharmaceutical companies, including Chengdu Institute of Biological Products, Chengdu Olin Biotechnology, and Luoyi (Wuxi) Biopharmaceutical, have developed or are evaluating versions of this vaccine in clinical trials to address the prevalence of these serogroups in the region.
- Other names
- Group A and C meningococcal conjugate vaccineMeningococcal Group A and Group C Polysaccharide Conjugate Vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal group A and C conjugate vaccine (Sinopharm).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A and C conjugate vaccine (Sinopharm).